Lipids and stroke: Neglect of a useful preventive measure?

Cardiovascular Research

Volumn 40, Issue 2, 1998, Pages 265-271

  Papadakis, John A ^a   Mikhailidis, Dimitri P ^a   Winder, Anthony F ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atherosclerosis; Cerebrovascular events; Ischaemic heart disease; Lipid lowering therapy; Lipids; Statins; Stroke; Stroke prevention

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CHOLESTEROL; CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; LIPIDS; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 0032213727     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00222-3     Document Type: Review

References (77)

1. [1] West of Scotland Coronary Prevention Study Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-1342.
2. [2] The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/l (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
3. [3] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. [4] American Heart Association. Heart and Stroke Facts: 1994 Statistical Supplement. Dallas: American Heart Association, 1993.
5. [5] Rastenyte D, Tuomilehto J, Domarkiene S, Cepaitis Z, Reklaitiene R. Risk factors for death from stroke in middle-aged Lithuanian men: results from a 20-year prospective study. Stroke 1996;27:672-676.
6. [6] Palmer A, Bulpitt C, Beevers G, et al. Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients. J Hum Hypertens 1995;9:695-697.
7. [7] Menotti A, Blackburn H, Kromhout D, et al. The inverse relation of average population blood pressure and stroke mortality rates in the seven countries study: a paradox. Eur J Epidemiol 1997;13:379-386.
8. [8] Prospective Studies Collaboration Group. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-1653.
9. [9] Emond MJ, Zareba W. Prognostic value of cholesterol in women of different ages. J Women Health 1997;6:295-307.
10. [10] Korn-Lubetzki I, Kleinman Y, Eliashiv S, Eliakim M. Correlation between serum lipids and stroke in an Israeli population. Neurol Res 1992;14(Suppl 2):78-80.
11. [11] World Health Organization. Tobacco or health: A global status report. Geneva: World Health Organization, 1997.
12. [12] Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990;131:579-588.
13. [13] Nakayama T, Date C, Yokoyama T, et al. A 15.5 year follow-up study of stroke in a Japanese provincial city. The Shibata Study. Stroke 1997;28:45-52.
14. [14] Seino F, Date C, Nakayama T, et al. Dietary lipids and incidence of cerebral infarction in a Japanese rural community. J Nutr Sci Vitaminol 1997;43:83-99.
15. [15] Mata P, Varela O, Alonso R, et al. Monounsaturated and polyunsaturated n-6 fatty acid-enriched diets modify LDL oxidation and decrease human coronary smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol 1997;17:2088-2095.
16. [16] De Lorgeril M, Salen P, Martin JL, et al. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996;28:1103-1108.
17. [17] Ferro-Luzzi A, Branca F. Mediterranean diet, Italian-style: prototype of a healthy diet. Am J Clin Nutr 1995;61(Suppl):1338S-1345S.
18. [18] Frank JW, Reed DM, Grove JS, Benfante R. Will lowering population levels of serum cholesterol affect total mortality? Expectations from the Honolulu Heart Program. J Clin Epidemiol 1992;45:333-346.
19. [19] Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460-1465.
20. [20] Ozawa H, Aono H, Saito I, Ikebe T. Atherosclerosis and clinical examination: epidemiology of stroke and ischemic heart disease. Rinsho Byori-Japan. J Clin Pathol 1996;44:1015-1026.
21. [21] Puddey IB. Low serum cholesterol and the risk of cerebral haemorrhage. Atherosclerosis 1996;119:1-6.
22. [22] Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 1996;27:1993-1998.
23. [23] Gatchev O, Rastam L, Lindberg G, et al. Subarachnoid haemorrhage, cerebral haemorrhage and serum cholesterol concentration in men and women. Ann Epidemiol 1993;3:403-409.
24. [24] Suzuki K, Sarti C, Tuomilehto J, et al. Stroke incidence and case fatality in Finland and in Akita. Japan: a comparative study. Neuroepidemiology 1994;13:236-244.
25. [25] Urakami K, Igo M, Takahashi K. An epidemiologic study of cerebrovascular disease in western Japan: with special reference to transient ischaemic attacks. Stroke 1987;18:396-401.
26. [26] Cheng XM, Ziegler DK, Lai YH, et al. Stroke in China, 1986 through 1990. Stroke 1995;26:1990-1994.
27. [27] Chang SF, Su CL, Chen ZY, Hung TP. Stroke incidence in Ilan, Taiwan. J Formos Med Assoc 1995;94:30-36.
28. [28] Iso H, Jacobs Jr. DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. New Engl J Med 1989;320:904-910.
29. [29] Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:1490-1500.
30. [30] Konishi M, Iso H, Komachi Y. et al. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 1993;24:954-964.
31. [31] Palomaki H, Kaste M, Raininko R, et al. Risk factors for cervical atherosclerosis in patients with transient ischaemic attack or minor ischemic stroke. Stroke 1993;24:970-975.
32. [32] Yoshinari M, Kaku R, Iwase M, et al. Development of ischaemic stroke in normotensive and hypertensive diabetic patients with or without antihypertensive treatment: an 8-year follow-up study. J Diabetes Complicat 1997;11:9-14.
33. [33] Fonte G, Bo M, Poli L, Fiandra U, Fabris F. Ischemic stroke and transient ischaemic attacks: a case-control study of the risk factors in elderly hospitalized patients. Recent Prog Med 1993;84:254-262.
34. [34] Jacobs DR. The relationship between cholesterol and stroke. Health Reports 1994;6:87-93.
35. [35] Di Mascio R, Marchioli R, Vitullo F, et al. Serum cholesterol and risk of ischaemic stroke: results of a case-control study. On behalf of PROGETTO 3A Investigators. Prev Med 1995;24:128-133.
36. [36] Bowlin SJ, Medalie JH, Flocke SA, et al. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol 1997;7:180-187.
37. [37] Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischaemic cerebrovascular disease. Stroke 1995;26:1841-1848.
38. [38] Hachinski V, Graffagnino C, Beaudry M, et al. Lipids and stroke: a paradox resolved. Arch Neurol 1996;53:303-308.
39. [39] Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein (a) levels are an independent risk factor for cerebral infraction. Stroke 1993;24:965-969.
40. [40] Yamamoto M, Egusa G, Yamakido M. Carotid atherosclerosis and serum lipoprotein (a) concentrations in patients with NIDDM. Diabetes Care 1997;20:829-831.
41. [41] Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischaemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischaemic Heart Disease Study. Stroke 1997;28:83-87.
42. [42] Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-68.
43. [43] Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high-density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. Br Med J 1994;309:11-15.
44. [44] Zeiler K, Siostrzonek P, Lang W, et al. Different risk factor profiles in young and elderly stroke patients with special reference to cardiac disorders. J Clin Epidemiol 1992;45:1383-1389.
45. [45] Sridharan R. Risk factors for ischaemic stroke: a case control analysis. Neuroepidemiology 1992;11:24-30.
46. [46] Atkins D, Psaty BM, Koepsell TD, Longstreth Jr. WT, Larson EB. Cholesterol reduction and the risk for stroke in men. A metaanalysis of randomized, controlled trials. Ann Intern Med 1993;119:136-145.
47. [47] Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995;155:50-55.
48. [48] Giroud M, Creisson E, Fayolle H, et al. Risk factors for primary cerebral haemorrhage: a population-based study-the Stroke Registry of Dijon. Neuroepidemiology 1995;14:20-26.
49. [49] Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med 1995;333:1301-1307.
50. [50] Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl J Med 1996;335:1001-1009.
51. [51] Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
52. [52] Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-1310.
53. [53] Hebert PR, Gaziano M, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality. J Am Med Assoc 1997;278:313-321.
54. th Scientific Sessions 1997, Orlando, USA (Abstract).
55. [55] Burcher HC, Griffith LE, Guyatt GH. Effect of HMG-CoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89-95.
56. [56] Dexter DD, Whisnant JP, Connolly DC, O'Fallon WM. The association of stroke and coronary heart disease: a population study. Mayo Clin Proc 1987;62:1077-1083.
57. [57] Dunabibin DW, Sandercock PAG. Preventing stroke by the modification of risk factors. Stroke 1990;21(Suppl IV):36-39.
58. [58] Alam R, Yatsu FM, Kasturi R, Bui G. Low and high-density lipoprotein metabolism in atherothrombotic brain infarction. Stroke 1992;23:1265-1270.
59. [59] Furberg CD, Adams Jr. HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-1687.
60. [60] Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995;75:455-459.
61. [61] Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-1764.
62. [62] Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996;23:755-766.
63. [63] Delathy N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997;28:2315-2320.
64. [64] Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-335.
65. [65] Ellis GR, Frenneaux MP. Statins: Non-coronary benefits of lipid-lowering. Br J Cardiol 1997;4(Suppl 1):S24-S27.
66. [66] Coumar A, Gill JK, Barradas MA, et al. The effect of treatment with simvastatin on platelet function indices in hypercholesterolaemia. J Drug Dev 1991;4:79-86.
67. [67] Mikhailidis DP, Ganotakis ES, Winder AF. Effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoprotienemia. Atherosclerosis 1996;127:287-288.
68. [68] O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131.
69. [69] Chen L, Haught WH, Yang B, et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997;30:569-575.
70. [70] Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082.
71. [71] Mikhailidis DP, Ganotakis ES, Jagroop IA, Winder AF. Beneficial effects of statins. Lancet 1996;348:1582-1583.
72. [72] Ganotakis ES, Mikhailidis DP. Bezafibrate: Treating hyperlipidaemias as well as other cardiovascular risk factors. Today Ther Trends 1996;13:231-249.
73. [73] Breimer LH, Ganotakis ES, Mikhailidis DP. Fibrinogen as a cardiovascular risk factor. Rev Port Cardiol 1997;16:245-250.
74. [74] Rothwell PM, Slattery J, Warlow CP. Clinical and angiographic predictors of stroke and death from carotid endarterectomy: systematic review. Br Med J 1997;315:1571-1577.
75. [75] Collins R, Petro R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.
76. [76] Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infraction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
77. [77] Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology 1997;16:107-115.